Fig. 5
From: Pharmacologic inhibition of IL11/STAT3 signaling increases MHC-I expression and T cell infiltration
IL11 mutein competitively inhibit IL11 to upregulate CXCL9 and MHC-I in tumor. A, B Immunoblot of STAT1/3 (total and phosphorylated) in IFNγ-induced (10 ng/ml), IL11-treated (100 ng/ml) MC38 with/without IL-11 mutein (100 ng/ml). STAT1/3 phosphorylation ratio was calculated. Data presented as means ± SD from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, t test. C mRNA expression of CXCL9, H2-D1, H2-K1 in IFNγ/IL11-treated MC38 with/without IL11 mutein treatment (100 ng/ml). Data presented as fold change to control group and means ± SEM from three independent experiments. *P < 0.05, **P < 0.01, t test. D Representative images of MC38 subcutaneous tumors with/without IL11 mutein treatment (10 mg/kg B.W.; n = 6 mice/group). E Tumor volume (cm3) of MC38 tumors with/without IL11 mutein treatment (n = 6 mice/group). ***P < 0.001, two-way ANOVA. F Tumor weight of MC38 tumors with/without IL11 mutein treatment (n = 6 mice/group). *P < 0.05, t test. G, H Immunofluorescence and cell counts of CD8 (yellow) and DAPI (blue) of IL11 mutein treated MC38 tumors (n = 6 mice/group). Scale bar, 50 μm. *P < 0.05, t test. I Ki-67 staining of MC38 tumors with/without IL11 mutein treatment. Scale bar, 50 μm. J Representative images of MC38 subcutaneous tumors in CD8α-depleted WT mice with/without IL11 mutein treatment (10 mg/kg B.W.; n = 6 mice/group). K Tumor volume (cm3) of MC38 tumors in CD8α-depleted WT mice with/without IL11 mutein treatment (n = 6 mice/group). ns, no significance, two-way ANOVA. L Tumor weight of MC38 tumors with/without IL11 mutein treatment (n = 6 mice/group). ns, no significance, t-test. M Survival curve of MC38-i.p.-injected mice treated with/without IL11 mutein (10 mg/kg B.W.; n = 10 mice/group). log rank p = 0.033